<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681184</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-GO1-003</org_study_id>
    <secondary_id>2018-001981-40</secondary_id>
    <nct_id>NCT03681184</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1</brief_title>
  <acronym>ILLUMINATE-A</acronym>
  <official_title>ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Lumasiran in Children and
      Adults with Primary Hyperoxaluria Type 1 (PH1).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Actual">November 5, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in 24-hour Urinary Oxalate Excretion from Baseline to Month 6</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in 24-hour Urinary Oxalate Corrected for Body Surface Area (BSA) from Baseline to Month 6</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Urinary Oxalate:Creatinine Ratio (Value/Upper Limit of Normal [ULN]) from Baseline to Month 6</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 24-hour Urinary Oxalate Level At or Below 1.5 x ULN at Month 6</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 24-hour Urinary Oxalate Level At or Below ULN at Month 6</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Plasma Oxalate from Baseline to Month 6</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Plasma Oxalate from Baseline to Month 6</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated Glomerular Filtration Rate (eGFR) from Baseline to Month 6</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in 24-hour Urinary Oxalate Excretion from Baseline over Time During the Extension Phase</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in 24-hour Urinary Oxalate Excretion from Baseline over Time During the Extension Phase</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time That 24-hour Urinary Oxalate is At or Below 1.5 Ã— ULN During the Extension Phase</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Urinary Oxalate:Creatinine Ratio (Value/Upper Limit of Normal [ULN]) from Baseline over Time During the Extension Phase</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated Glomerular Filtration Rate (eGFR) from Baseline over Time During the Extension Phase</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Primary Hyperoxaluria Type 1 (PH1)</condition>
  <arm_group>
    <arm_group_label>Lumasiran (ALN-GO1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumasiran</intervention_name>
    <description>Multiple doses of lumasiran by subcutaneous (SC) injection</description>
    <arm_group_label>Lumasiran (ALN-GO1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>Calculated volume to match experimental</description>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to provide written informed consent or assent and to comply with study
             requirements

          -  Confirmation of PH1 disease

          -  Meet the 24 hour urine oxalate excretion requirements

          -  If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90
             days

        Exclusion Criteria:

          -  Clinically significant health concerns (with the exception of PH1) or clinical
             evidence of extrarenal systemic oxalosis

          -  Clinically significant abnormal laboratory results

          -  Known active or evidence of HIV or hepatitis B or C infection

          -  An estimated GFR of &lt; 30 mL/min/1.73m2 at screening

          -  Received an investigational agent within 30 days or 5 half-lives before the first dose
             of study drug or are in follow-up of another clinical study

          -  History of kidney or liver transplant

          -  Known history of multiple drug allergies or allergic reaction to an oligonucleotide or
             GalNAc

          -  History of intolerance to subcutaneous injection

          -  Women who are pregnant, planning a pregnancy, or breast-feeding or those of child
             bearing potential and not willing to use contraception

          -  History of alcohol abuse within the last 12 months, or unable or unwilling to limit
             alcohol consumption throughout the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Gansner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PH1</keyword>
  <keyword>Primary Hyperoxaluria</keyword>
  <keyword>RNAi therapeutic</keyword>
  <keyword>siRNA</keyword>
  <keyword>AGT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

